Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. BETASERC TABLETS 16 MG [SIN11365P]

BETASERC TABLETS 16 MG [SIN11365P]

Active ingredients: BETASERC TABLETS 16 MG

Last updated 26 October 2025

Product Info

BETASERC TABLETS 16 MG

[SIN11365P]

Product information

Active Ingredient and Strength

BETAHISTINE 2HCL - 16 MG

Dosage Form

TABLET

Manufacturer and Country

MYLAN LABORATORIES SAS - FRANCE

Registration Number

SIN11365P

Licence Holder

ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

N07CA01

Therapeutic Indications
Ménière’s Syndrome as defined by the following core symptoms:

  • vertigo (with nausea/vomiting)

  • hearing loss (hardness of hearing)

  • tinnitus (ringing in the ears)

Symptomatic treatment of vestibular vertigo.

Posology and method of administration
The dosage for adults is 24–48 mg divided over the day.

Betaserc Dosage Table 1



Should be swallowed with water.

The dosage should be individually adapted according to the response. Improvement can sometimes only be observed after a couple of weeks of treatment. The best results are sometimes obtained only after a few months. There are indications that treatment from the onset of the disease prevents its progression and/or the loss of hearing in later phases of the disease.

Pediatric population:
Betaserc is not recommended for use in children under the age of 18 years due to insufficient data on safety and efficacy.

Contraindications
Hypersensitivity to the active substance or to any of the excipients.
Phaeochromocytoma.